Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-02-07 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Transaction in Own Shares Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release about a share buyback agreement. The document length is short (1287 characters) and it mainly announces the execution of a share buyback agreement, which is a capital activity. There is no detailed financial data or comprehensive report content. According to the rules, this is an announcement related to capital structure changes, specifically a share repurchase. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2025-02-07 English
Press Release: Execution of a share buyback agreement for up to €2 billion
Transaction in Own Shares Classification · 100% confidence The document is a press release announcing the execution of a share buyback mandate for up to €2 billion. This falls under the category of a company buying back its own shares, which is explicitly defined as 'Transaction in Own Shares' (POS).
2025-02-07 English
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 2 milliards d’euros
Transaction in Own Shares Classification · 100% confidence The document is a press release from Sanofi announcing the signing of a share repurchase mandate for up to 2 billion euros. This falls under the category of a company buying back its own shares. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports of a company buying back or selling its own shares.
2025-02-07 French
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes references to press releases attached as exhibits, specifically about a drug approval and a share buyback announcement. The document is relatively short (1543 characters) and primarily serves as a regulatory filing to inform the SEC and investors about recent events. It does not contain detailed financial statements, management discussion, or comprehensive report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-02-03 English
Communiqué de presse : Sanofi annonce un rachat d'actions à L'Oréal
Transaction in Own Shares Classification · 100% confidence The document is a press release ('Communiqué de presse') dated February 3, 2025, announcing that Sanofi is acquiring 2.3% of its own shares from L'Oréal. The core subject is a share repurchase transaction ('rachat d'actions') involving the cancellation of shares and its impact on EPS. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs. It is not a full Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it details a specific corporate action related to capital management.
2025-02-03 French
Press Release: Sanofi announces buy back of shares from L’Oréal
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Press Release' and announces the 'acquisition of 2.3% of its shares from long-standing shareholder L'Oréal' as part of Sanofi's 'share buyback program'. It details the transaction structure (block trade), price, total consideration (€3 billion), and the intention to cancel the shares. This activity—the company purchasing its own stock—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing code is POS.
2025-02-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.